PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Savoldi, A.* ; Morra, M.* ; Castelli, A.* ; Mirandola, M.* ; Berkell, M.* ; Smet, M.* ; Konnova, A.* ; Rossi, E.* ; Cataudella, S.* ; De Nardo, P.* ; Gentilotti, E.* ; Gupta, A.* ; Fasan, D.* ; Gibbin, E.* ; Puviani, F.C.* ; Hasenauer, J. ; Gusinow, R. ; Tami, A.* ; Kumar-Singh, S.* ; Malhotra-Kumar, S.* ; Tacconelli, E.*

Clinical impact of monoclonal antibodies in the treatment of high-risk patients with SARS-CoV-2 breakthrough infections: The ORCHESTRA prospective cohort study.

Biomedicines 10:2063 (2022)
Verlagsversion Forschungsdaten DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
The clinical impact of anti-spike monoclonal antibodies (mAb) in Coronavirus Disease 2019 (COVID-19) breakthrough infections is unclear. We present the results of an observational prospective cohort study assessing and comparing COVID-19 progression in high-risk outpatients receiving mAb according to primary or breakthrough infection. Clinical, serological and virological predictors associated with 28-day COVID-19-related hospitalization were identified using multivariate logistic regression and summarized with odds ratio (aOR) and 95% confidence interval (CI). A total of 847 COVID-19 outpatients were included: 414 with primary and 433 with breakthrough infection. Hospitalization was observed in 42/414 (10.1%) patients with primary and 8/433 (1.8%) patients with breakthrough infection (p < 0.001). aOR for hospitalization was significantly lower for breakthrough infection (aOR 0.12, 95%CI: 0.05–0.27, p < 0.001) and higher for immunocompromised status (aOR:2.35, 95%CI:1.08–5.08, p = 0.003), advanced age (aOR:1.06, 95%CI: 1.03–1.08, p < 0.001), and male gender (aOR:1.97, 95%CI: 1.04–3.73, p = 0.037). Among the breakthrough infection group, the median SARS-CoV-2 anti-spike IgGs was lower (p < 0.001) in immunocompromised and elderly patients >75 years compared with that in the immunocompetent patients. Our findings suggest that, among mAb patients, those with breakthrough infection have significantly lower hospitalization risk compared with patients with primary infection. Prognostic algorithms combining clinical and immune-virological characteristics are needed to ensure appropriate and up-to-date clinical protocols targeting high-risk categories.
Impact Factor
Scopus SNIP
Altmetric
4.757
0.000
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Anti-spike Monoclonal Antibodies ; Covid-19 Breakthrough Infection ; Covid-19 Early Treatment
Sprache englisch
Veröffentlichungsjahr 2022
HGF-Berichtsjahr 2022
ISSN (print) / ISBN 2227-9059
e-ISSN 2227-9059
Zeitschrift Biomedicines
Quellenangaben Band: 10, Heft: 9, Seiten: , Artikelnummer: 2063 Supplement: ,
Verlag MDPI
Verlagsort Basel, Switzerland
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Computational Biology (ICB)
POF Topic(s) 30205 - Bioengineering and Digital Health
Forschungsfeld(er) Enabling and Novel Technologies
PSP-Element(e) G-553800-001
G-503800-010
DOI 10.3390/biomedicines10092063
WOS ID WOS:000858524500001
Scopus ID 85138689702
PubMed ID 36140162
Erfassungsdatum 2022-11-21
[➜Korrektur melden]